Cost-Effectiveness of Insulin Degludec vs. Insulin Glargine U100 in Type 1 and Type 2 Diabetes Mellitus in a UK Setting View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2018-10

AUTHORS

Marc Evans, Roopa Mehta, Jens Gundgaard, Barrie Chubb

ABSTRACT

BACKGROUND: Understanding which therapeutic innovations in diabetes represent the best value requires rigorous economic evaluation. Data from randomised controlled trials and observational studies indicate that insulin degludec has a hypoglycemia advantage versus insulin glargine 100 units/mL (glargine U100), the most widely prescribed basal insulin analogue in the UK. This analysis was done to more rigorously assess cost-effectiveness in a UK setting. METHODS: Data from two double-blinded, randomised, two-period crossover trials in type 1 (SWITCH 1) and type 2 (SWITCH 2) diabetes mellitus were used to assess the cost-effectiveness of degludec vs. glargine U100 with an economic model. Cost-effectiveness was analysed over a 1-year time horizon based on the different rates of hypoglycaemia and actual doses of insulin used, rather than glycaemic control due to the treat-to-target trial design. RESULTS: In type 1 diabetes mellitus, degludec was highly cost-effective compared with glargine U100, with an incremental cost-effectiveness ratio of £984 (increased costs of only £23/year and improvement in participant health of 0.0232 quality-adjusted life-years (QALYs)). In type 2 diabetes mellitus, it was estimated that quality of life was improved (0.0065 QALYs gain) with degludec compared with glargine U100 at an increased annual cost of £117 (incremental cost-effectiveness ratio, £17,939). One-way sensitivity analyses showed that the results were robust to changes in parameters in both type 1 and type 2 diabetes mellitus. CONCLUSIONS: The rigorous design of the SWITCH trials, coupled with a representative patient population and a definition of hypoglycaemia that is relevant for real-world patients, makes the results of these trials highly generalisable. The within-trial analysis has the added value of being able to include doses and event rates directly from the trials. This short-term economic analysis estimated that IDeg would be cost-effective relative to IGlar U100 in both type 1 and type 2 diabetes mellitus in the UK. TRIAL REGISTRATION: SWITCH 1 (NCT02034513); SWITCH 2 (NCT02030600). FUNDING: Novo Nordisk, Søborg, Denmark. More... »

PAGES

1919-1930

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s13300-018-0478-1

DOI

http://dx.doi.org/10.1007/s13300-018-0478-1

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1106098047

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30097995


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1402", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Applied Economics", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/14", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Economics", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "University Hospital Llandough", 
          "id": "https://www.grid.ac/institutes/grid.416025.4", 
          "name": [
            "University Hospital Llandough, Penarth, Cardiff, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Evans", 
        "givenName": "Marc", 
        "id": "sg:person.01167546340.80", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01167546340.80"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Instituto Nacional de Ciencias M\u00e9dicas y Nutrici\u00f3n Salvador Zubir\u00e1n", 
          "id": "https://www.grid.ac/institutes/grid.416850.e", 
          "name": [
            "Departamento de Endocrinologia y Metabolismo, Instituto Nacional de Ciencias M\u00e9dicas y Nutricion Salvador Zubiran, Vasco de Quiroga 15, Mexico City, Mexico"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mehta", 
        "givenName": "Roopa", 
        "id": "sg:person.0647030077.37", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0647030077.37"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novo Nordisk (Denmark)", 
          "id": "https://www.grid.ac/institutes/grid.425956.9", 
          "name": [
            "Novo Nordisk A/S, S\u00f8borg, Denmark"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gundgaard", 
        "givenName": "Jens", 
        "id": "sg:person.0610060240.74", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0610060240.74"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novo Nordisk (United Kingdom)", 
          "id": "https://www.grid.ac/institutes/grid.436696.8", 
          "name": [
            "Novo Nordisk, Crawley, West Sussex, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chubb", 
        "givenName": "Barrie", 
        "id": "sg:person.01067301036.89", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01067301036.89"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1586/erp.11.73", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000082736"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/dom.12250", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000463471"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/dme.13317", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002556256"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1586/erp.12.80", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004558475"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1185/030079907x182194", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010375883"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3111/13696990903336597", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011407413"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2337/dc14-0405", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011430325"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1464-5491.2012.03657.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012309405"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1477-7525-11-90", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013049175", 
          "https://doi.org/10.1186/1477-7525-11-90"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00019053-199609020-00003", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013124547", 
          "https://doi.org/10.2165/00019053-199609020-00003"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.diabres.2008.04.007", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021927937"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2337/dc10-1915", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022803953"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3111/13696998.2014.971160", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023138240"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.jcjd.2015.09.009", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023224366"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1463-1326.2012.01627.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024357147"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/dme.12844", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025550716"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3111/13696998.2014.975234", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030412243"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1463-1326.2008.00976.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033725773"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1185/030079904x5661", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034499493"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2337/dc12-2480", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035642945"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/dom.12032", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036450839"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s13300-016-0157-z", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038704969", 
          "https://doi.org/10.1007/s13300-016-0157-z"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1463-1326.2012.01638.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040850913"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2147/ppa.s46805", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043777846"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.jval.2015.09.2118", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044795257"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2337/dc14-0920", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045441239"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1080/03007995.2016.1277194", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045753301"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/1753-0407.12266", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049208743"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1463-1326.2008.00845.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053534325"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1089/dia.2012.0031", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1059249659"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3402/jmahp.v1i0.21240", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1071274168"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s13300-017-0236-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083845661", 
          "https://doi.org/10.1007/s13300-017-0236-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s13300-017-0236-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083845661", 
          "https://doi.org/10.1007/s13300-017-0236-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/jama.2017.7117", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1090330206"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/jama.2017.7115", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1090332621"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2018-10", 
    "datePublishedReg": "2018-10-01", 
    "description": "BACKGROUND: Understanding which therapeutic innovations in diabetes represent the best value requires rigorous economic evaluation. Data from randomised controlled trials and observational studies indicate that insulin degludec has a hypoglycemia advantage versus insulin glargine 100 units/mL (glargine U100), the most widely prescribed basal insulin analogue in the UK. This analysis was done to more rigorously assess cost-effectiveness in a UK setting.\nMETHODS: Data from two double-blinded, randomised, two-period crossover trials in type 1 (SWITCH 1) and type 2 (SWITCH 2) diabetes mellitus were used to assess the cost-effectiveness of degludec vs. glargine U100 with an economic model. Cost-effectiveness was analysed over a 1-year time horizon based on the different rates of hypoglycaemia and actual doses of insulin used, rather than glycaemic control due to the treat-to-target trial design.\nRESULTS: In type 1 diabetes mellitus, degludec was highly cost-effective compared with glargine U100, with an incremental cost-effectiveness ratio of \u00a3984 (increased costs of only \u00a323/year and improvement in participant health of 0.0232 quality-adjusted life-years (QALYs)). In type 2 diabetes mellitus, it was estimated that quality of life was improved (0.0065 QALYs gain) with degludec compared with glargine U100 at an increased annual cost of \u00a3117 (incremental cost-effectiveness ratio, \u00a317,939). One-way sensitivity analyses showed that the results were robust to changes in parameters in both type 1 and type 2 diabetes mellitus.\nCONCLUSIONS: The rigorous design of the SWITCH trials, coupled with a representative patient population and a definition of hypoglycaemia that is relevant for real-world patients, makes the results of these trials highly generalisable. The within-trial analysis has the added value of being able to include doses and event rates directly from the trials. This short-term economic analysis estimated that IDeg would be cost-effective relative to IGlar U100 in both type 1 and type 2 diabetes mellitus in the UK.\nTRIAL REGISTRATION: SWITCH 1 (NCT02034513); SWITCH 2 (NCT02030600).\nFUNDING: Novo Nordisk, S\u00f8borg, Denmark.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s13300-018-0478-1", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1044057", 
        "issn": [
          "1869-6953", 
          "1869-6961"
        ], 
        "name": "Diabetes Therapy", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "5", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "9"
      }
    ], 
    "name": "Cost-Effectiveness of Insulin Degludec vs. Insulin Glargine U100 in Type 1 and Type 2 Diabetes Mellitus in a UK Setting", 
    "pagination": "1919-1930", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "fbffdc7d4c1e35c40e99a83b36acfd8dd25b424e1b6da7a2d7bd46e417e9113b"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30097995"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "101539025"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s13300-018-0478-1"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1106098047"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s13300-018-0478-1", 
      "https://app.dimensions.ai/details/publication/pub.1106098047"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T00:24", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8695_00000562.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1007%2Fs13300-018-0478-1"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s13300-018-0478-1'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s13300-018-0478-1'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s13300-018-0478-1'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s13300-018-0478-1'


 

This table displays all metadata directly associated to this object as RDF triples.

205 TRIPLES      21 PREDICATES      63 URIs      21 LITERALS      9 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s13300-018-0478-1 schema:about anzsrc-for:14
2 anzsrc-for:1402
3 schema:author Nb4bc687ad4464b0ca9c5652b6c4764fd
4 schema:citation sg:pub.10.1007/s13300-016-0157-z
5 sg:pub.10.1007/s13300-017-0236-9
6 sg:pub.10.1186/1477-7525-11-90
7 sg:pub.10.2165/00019053-199609020-00003
8 https://doi.org/10.1001/jama.2017.7115
9 https://doi.org/10.1001/jama.2017.7117
10 https://doi.org/10.1016/j.diabres.2008.04.007
11 https://doi.org/10.1016/j.jcjd.2015.09.009
12 https://doi.org/10.1016/j.jval.2015.09.2118
13 https://doi.org/10.1080/03007995.2016.1277194
14 https://doi.org/10.1089/dia.2012.0031
15 https://doi.org/10.1111/1753-0407.12266
16 https://doi.org/10.1111/dme.12844
17 https://doi.org/10.1111/dme.13317
18 https://doi.org/10.1111/dom.12032
19 https://doi.org/10.1111/dom.12250
20 https://doi.org/10.1111/j.1463-1326.2008.00845.x
21 https://doi.org/10.1111/j.1463-1326.2008.00976.x
22 https://doi.org/10.1111/j.1463-1326.2012.01627.x
23 https://doi.org/10.1111/j.1463-1326.2012.01638.x
24 https://doi.org/10.1111/j.1464-5491.2012.03657.x
25 https://doi.org/10.1185/030079904x5661
26 https://doi.org/10.1185/030079907x182194
27 https://doi.org/10.1586/erp.11.73
28 https://doi.org/10.1586/erp.12.80
29 https://doi.org/10.2147/ppa.s46805
30 https://doi.org/10.2337/dc10-1915
31 https://doi.org/10.2337/dc12-2480
32 https://doi.org/10.2337/dc14-0405
33 https://doi.org/10.2337/dc14-0920
34 https://doi.org/10.3111/13696990903336597
35 https://doi.org/10.3111/13696998.2014.971160
36 https://doi.org/10.3111/13696998.2014.975234
37 https://doi.org/10.3402/jmahp.v1i0.21240
38 schema:datePublished 2018-10
39 schema:datePublishedReg 2018-10-01
40 schema:description BACKGROUND: Understanding which therapeutic innovations in diabetes represent the best value requires rigorous economic evaluation. Data from randomised controlled trials and observational studies indicate that insulin degludec has a hypoglycemia advantage versus insulin glargine 100 units/mL (glargine U100), the most widely prescribed basal insulin analogue in the UK. This analysis was done to more rigorously assess cost-effectiveness in a UK setting. METHODS: Data from two double-blinded, randomised, two-period crossover trials in type 1 (SWITCH 1) and type 2 (SWITCH 2) diabetes mellitus were used to assess the cost-effectiveness of degludec vs. glargine U100 with an economic model. Cost-effectiveness was analysed over a 1-year time horizon based on the different rates of hypoglycaemia and actual doses of insulin used, rather than glycaemic control due to the treat-to-target trial design. RESULTS: In type 1 diabetes mellitus, degludec was highly cost-effective compared with glargine U100, with an incremental cost-effectiveness ratio of £984 (increased costs of only £23/year and improvement in participant health of 0.0232 quality-adjusted life-years (QALYs)). In type 2 diabetes mellitus, it was estimated that quality of life was improved (0.0065 QALYs gain) with degludec compared with glargine U100 at an increased annual cost of £117 (incremental cost-effectiveness ratio, £17,939). One-way sensitivity analyses showed that the results were robust to changes in parameters in both type 1 and type 2 diabetes mellitus. CONCLUSIONS: The rigorous design of the SWITCH trials, coupled with a representative patient population and a definition of hypoglycaemia that is relevant for real-world patients, makes the results of these trials highly generalisable. The within-trial analysis has the added value of being able to include doses and event rates directly from the trials. This short-term economic analysis estimated that IDeg would be cost-effective relative to IGlar U100 in both type 1 and type 2 diabetes mellitus in the UK. TRIAL REGISTRATION: SWITCH 1 (NCT02034513); SWITCH 2 (NCT02030600). FUNDING: Novo Nordisk, Søborg, Denmark.
41 schema:genre research_article
42 schema:inLanguage en
43 schema:isAccessibleForFree true
44 schema:isPartOf N15b4fa4a7aa14477b35773f5b0abf730
45 Nd26bad860b9c4fe2aa5c4e98e3e8737b
46 sg:journal.1044057
47 schema:name Cost-Effectiveness of Insulin Degludec vs. Insulin Glargine U100 in Type 1 and Type 2 Diabetes Mellitus in a UK Setting
48 schema:pagination 1919-1930
49 schema:productId N1057929785a8411abf9eff619d940f5b
50 N23e72611d51b4465850c3b7d5ab7abf5
51 N5063919235204484b9ca97c861bdd8e6
52 N7d88bb9cd3694a8192831134603d8741
53 N96f0902fa1d34df6bcd60f90b8458b91
54 schema:sameAs https://app.dimensions.ai/details/publication/pub.1106098047
55 https://doi.org/10.1007/s13300-018-0478-1
56 schema:sdDatePublished 2019-04-11T00:24
57 schema:sdLicense https://scigraph.springernature.com/explorer/license/
58 schema:sdPublisher Nfb00270becf246019c4e9e4e336144d6
59 schema:url https://link.springer.com/10.1007%2Fs13300-018-0478-1
60 sgo:license sg:explorer/license/
61 sgo:sdDataset articles
62 rdf:type schema:ScholarlyArticle
63 N0ab990a3ef474fdc857af6bb8afe6016 rdf:first sg:person.01067301036.89
64 rdf:rest rdf:nil
65 N1057929785a8411abf9eff619d940f5b schema:name dimensions_id
66 schema:value pub.1106098047
67 rdf:type schema:PropertyValue
68 N15b4fa4a7aa14477b35773f5b0abf730 schema:issueNumber 5
69 rdf:type schema:PublicationIssue
70 N23e72611d51b4465850c3b7d5ab7abf5 schema:name doi
71 schema:value 10.1007/s13300-018-0478-1
72 rdf:type schema:PropertyValue
73 N5063919235204484b9ca97c861bdd8e6 schema:name readcube_id
74 schema:value fbffdc7d4c1e35c40e99a83b36acfd8dd25b424e1b6da7a2d7bd46e417e9113b
75 rdf:type schema:PropertyValue
76 N7d88bb9cd3694a8192831134603d8741 schema:name pubmed_id
77 schema:value 30097995
78 rdf:type schema:PropertyValue
79 N96f0902fa1d34df6bcd60f90b8458b91 schema:name nlm_unique_id
80 schema:value 101539025
81 rdf:type schema:PropertyValue
82 Nb4bc687ad4464b0ca9c5652b6c4764fd rdf:first sg:person.01167546340.80
83 rdf:rest Nb8c5f1dd5a4b41a192ad2750a54f8cf4
84 Nb8c5f1dd5a4b41a192ad2750a54f8cf4 rdf:first sg:person.0647030077.37
85 rdf:rest Nfacff47dd2e241408a99db4cdf2bdebd
86 Nd26bad860b9c4fe2aa5c4e98e3e8737b schema:volumeNumber 9
87 rdf:type schema:PublicationVolume
88 Nfacff47dd2e241408a99db4cdf2bdebd rdf:first sg:person.0610060240.74
89 rdf:rest N0ab990a3ef474fdc857af6bb8afe6016
90 Nfb00270becf246019c4e9e4e336144d6 schema:name Springer Nature - SN SciGraph project
91 rdf:type schema:Organization
92 anzsrc-for:14 schema:inDefinedTermSet anzsrc-for:
93 schema:name Economics
94 rdf:type schema:DefinedTerm
95 anzsrc-for:1402 schema:inDefinedTermSet anzsrc-for:
96 schema:name Applied Economics
97 rdf:type schema:DefinedTerm
98 sg:journal.1044057 schema:issn 1869-6953
99 1869-6961
100 schema:name Diabetes Therapy
101 rdf:type schema:Periodical
102 sg:person.01067301036.89 schema:affiliation https://www.grid.ac/institutes/grid.436696.8
103 schema:familyName Chubb
104 schema:givenName Barrie
105 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01067301036.89
106 rdf:type schema:Person
107 sg:person.01167546340.80 schema:affiliation https://www.grid.ac/institutes/grid.416025.4
108 schema:familyName Evans
109 schema:givenName Marc
110 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01167546340.80
111 rdf:type schema:Person
112 sg:person.0610060240.74 schema:affiliation https://www.grid.ac/institutes/grid.425956.9
113 schema:familyName Gundgaard
114 schema:givenName Jens
115 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0610060240.74
116 rdf:type schema:Person
117 sg:person.0647030077.37 schema:affiliation https://www.grid.ac/institutes/grid.416850.e
118 schema:familyName Mehta
119 schema:givenName Roopa
120 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0647030077.37
121 rdf:type schema:Person
122 sg:pub.10.1007/s13300-016-0157-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1038704969
123 https://doi.org/10.1007/s13300-016-0157-z
124 rdf:type schema:CreativeWork
125 sg:pub.10.1007/s13300-017-0236-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083845661
126 https://doi.org/10.1007/s13300-017-0236-9
127 rdf:type schema:CreativeWork
128 sg:pub.10.1186/1477-7525-11-90 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013049175
129 https://doi.org/10.1186/1477-7525-11-90
130 rdf:type schema:CreativeWork
131 sg:pub.10.2165/00019053-199609020-00003 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013124547
132 https://doi.org/10.2165/00019053-199609020-00003
133 rdf:type schema:CreativeWork
134 https://doi.org/10.1001/jama.2017.7115 schema:sameAs https://app.dimensions.ai/details/publication/pub.1090332621
135 rdf:type schema:CreativeWork
136 https://doi.org/10.1001/jama.2017.7117 schema:sameAs https://app.dimensions.ai/details/publication/pub.1090330206
137 rdf:type schema:CreativeWork
138 https://doi.org/10.1016/j.diabres.2008.04.007 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021927937
139 rdf:type schema:CreativeWork
140 https://doi.org/10.1016/j.jcjd.2015.09.009 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023224366
141 rdf:type schema:CreativeWork
142 https://doi.org/10.1016/j.jval.2015.09.2118 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044795257
143 rdf:type schema:CreativeWork
144 https://doi.org/10.1080/03007995.2016.1277194 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045753301
145 rdf:type schema:CreativeWork
146 https://doi.org/10.1089/dia.2012.0031 schema:sameAs https://app.dimensions.ai/details/publication/pub.1059249659
147 rdf:type schema:CreativeWork
148 https://doi.org/10.1111/1753-0407.12266 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049208743
149 rdf:type schema:CreativeWork
150 https://doi.org/10.1111/dme.12844 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025550716
151 rdf:type schema:CreativeWork
152 https://doi.org/10.1111/dme.13317 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002556256
153 rdf:type schema:CreativeWork
154 https://doi.org/10.1111/dom.12032 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036450839
155 rdf:type schema:CreativeWork
156 https://doi.org/10.1111/dom.12250 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000463471
157 rdf:type schema:CreativeWork
158 https://doi.org/10.1111/j.1463-1326.2008.00845.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1053534325
159 rdf:type schema:CreativeWork
160 https://doi.org/10.1111/j.1463-1326.2008.00976.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1033725773
161 rdf:type schema:CreativeWork
162 https://doi.org/10.1111/j.1463-1326.2012.01627.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1024357147
163 rdf:type schema:CreativeWork
164 https://doi.org/10.1111/j.1463-1326.2012.01638.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1040850913
165 rdf:type schema:CreativeWork
166 https://doi.org/10.1111/j.1464-5491.2012.03657.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1012309405
167 rdf:type schema:CreativeWork
168 https://doi.org/10.1185/030079904x5661 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034499493
169 rdf:type schema:CreativeWork
170 https://doi.org/10.1185/030079907x182194 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010375883
171 rdf:type schema:CreativeWork
172 https://doi.org/10.1586/erp.11.73 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000082736
173 rdf:type schema:CreativeWork
174 https://doi.org/10.1586/erp.12.80 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004558475
175 rdf:type schema:CreativeWork
176 https://doi.org/10.2147/ppa.s46805 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043777846
177 rdf:type schema:CreativeWork
178 https://doi.org/10.2337/dc10-1915 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022803953
179 rdf:type schema:CreativeWork
180 https://doi.org/10.2337/dc12-2480 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035642945
181 rdf:type schema:CreativeWork
182 https://doi.org/10.2337/dc14-0405 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011430325
183 rdf:type schema:CreativeWork
184 https://doi.org/10.2337/dc14-0920 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045441239
185 rdf:type schema:CreativeWork
186 https://doi.org/10.3111/13696990903336597 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011407413
187 rdf:type schema:CreativeWork
188 https://doi.org/10.3111/13696998.2014.971160 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023138240
189 rdf:type schema:CreativeWork
190 https://doi.org/10.3111/13696998.2014.975234 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030412243
191 rdf:type schema:CreativeWork
192 https://doi.org/10.3402/jmahp.v1i0.21240 schema:sameAs https://app.dimensions.ai/details/publication/pub.1071274168
193 rdf:type schema:CreativeWork
194 https://www.grid.ac/institutes/grid.416025.4 schema:alternateName University Hospital Llandough
195 schema:name University Hospital Llandough, Penarth, Cardiff, UK
196 rdf:type schema:Organization
197 https://www.grid.ac/institutes/grid.416850.e schema:alternateName Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán
198 schema:name Departamento de Endocrinologia y Metabolismo, Instituto Nacional de Ciencias Médicas y Nutricion Salvador Zubiran, Vasco de Quiroga 15, Mexico City, Mexico
199 rdf:type schema:Organization
200 https://www.grid.ac/institutes/grid.425956.9 schema:alternateName Novo Nordisk (Denmark)
201 schema:name Novo Nordisk A/S, Søborg, Denmark
202 rdf:type schema:Organization
203 https://www.grid.ac/institutes/grid.436696.8 schema:alternateName Novo Nordisk (United Kingdom)
204 schema:name Novo Nordisk, Crawley, West Sussex, UK
205 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...